Disability-related costs from multiple sclerosis (MS) can be substantial, with estimated employer costs exceeding $1 billion annually. This study uses actuarial models to analyze various scenarios of reduced disease progression and their associated impact on disability costs. As newer treatments become available to slow the progression of MS, Sanofi recently commissioned Milliman to quantify the cost of disability in the commercially insured MS population and the expected impact under scenarios of slowing disability accumulation. This report summarizes the findings from this study.

We discuss:

• The recent shift in focus: From managing relapses to slowing disease progression
• Challenges for employers
• Assessing the cost burden of MS-related disability to employers
• Results: Distributions of MS patients and estimated costs to employers

This report was commissioned by Sanofi.